全文获取类型
收费全文 | 235699篇 |
免费 | 5568篇 |
国内免费 | 332篇 |
专业分类
耳鼻咽喉 | 1747篇 |
儿科学 | 8112篇 |
妇产科学 | 4510篇 |
基础医学 | 24049篇 |
口腔科学 | 3051篇 |
临床医学 | 18482篇 |
内科学 | 44461篇 |
皮肤病学 | 1455篇 |
神经病学 | 21205篇 |
特种医学 | 10715篇 |
外国民族医学 | 2篇 |
外科学 | 38064篇 |
综合类 | 3309篇 |
现状与发展 | 1篇 |
一般理论 | 103篇 |
预防医学 | 23094篇 |
眼科学 | 4557篇 |
药学 | 13738篇 |
中国医学 | 762篇 |
肿瘤学 | 20182篇 |
出版年
2023年 | 268篇 |
2022年 | 391篇 |
2021年 | 1156篇 |
2020年 | 726篇 |
2019年 | 1019篇 |
2018年 | 22972篇 |
2017年 | 18072篇 |
2016年 | 20299篇 |
2015年 | 2007篇 |
2014年 | 2510篇 |
2013年 | 3504篇 |
2012年 | 10572篇 |
2011年 | 24825篇 |
2010年 | 20932篇 |
2009年 | 13522篇 |
2008年 | 23214篇 |
2007年 | 25577篇 |
2006年 | 4461篇 |
2005年 | 6170篇 |
2004年 | 7108篇 |
2003年 | 7689篇 |
2002年 | 5809篇 |
2001年 | 978篇 |
2000年 | 1017篇 |
1999年 | 870篇 |
1998年 | 929篇 |
1997年 | 802篇 |
1996年 | 575篇 |
1995年 | 583篇 |
1994年 | 558篇 |
1993年 | 495篇 |
1992年 | 566篇 |
1991年 | 592篇 |
1990年 | 536篇 |
1989年 | 510篇 |
1988年 | 446篇 |
1987年 | 410篇 |
1986年 | 376篇 |
1985年 | 447篇 |
1984年 | 450篇 |
1983年 | 414篇 |
1982年 | 552篇 |
1981年 | 443篇 |
1980年 | 524篇 |
1979年 | 303篇 |
1978年 | 329篇 |
1977年 | 324篇 |
1976年 | 269篇 |
1975年 | 292篇 |
1974年 | 263篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
Edward M Messing Judith Manola George Wilding Kathleen Propert Jonathan Fleischmann E David Crawford J Edson Pontes Richard Hahn Donald Trump 《Journal of clinical oncology》2003,21(7):1214-1222
PURPOSE: To evaluate the role of adjuvant interferon alfa after complete resection of locally extensive renal cell carcinoma. PATIENTS AND METHODS: A total of 283 eligible patients with pT3-4a and/or node-positive disease were randomly assigned after radical nephrectomy and lymphadenectomy to observation or to interferon alfa-NL (Wellferon, Burroughs-Wellcome, Research Park, NC) given daily for 5 days every 3 weeks for up to 12 cycles. Patients were stratified on the basis of pathologic stage. Patients remained on treatment until documented recurrence, excessive toxicity, or patient/physician preference deemed removal appropriate. RESULTS: At median follow-up of 10.4 years, median survival was 7.4 years in the observation arm and 5.1 year in the treatment arm (log-rank P =.09). Median recurrence-free survival was 3.0 years in the observation arm and 2.2 years in the interferon arm (P =.33). Performance status (P =.003), nodal status (N2 v N0, P <.0001), and tumor stage (P =.0002) were significant prognostic factors in multivariate analysis. A proportional hazards model examining the effects of treatment arm and time to recurrence on survival after recurrence among patients who recurred found that random assignment to interferon treatment (P =.009) and shorter time to recurrence (P <.0001) were independent predictors of shorter survival after recurrence. Although no lethal toxicities were observed, severe (grade 4) toxicities including neutropenia, myalgia, fatigue, depression, and other neurologic toxicities occurred in 11.4% of those randomly assigned to interferon treatment. CONCLUSION: Adjuvant treatment with interferon did not contribute to survival or relapse-free survival in this group of patients. 相似文献
72.
73.
74.
Sergio Barroilhet Adrián Cano-Prous Salvador Cervera-Enguix Maria João Forjaz Francisco Guillén-Grima 《Social psychiatry and psychiatric epidemiology》2009,44(12):1051-1065
Introduction
This paper presents the results of a study on the psychometric properties of an authorized Spanish version of the McMaster Family Assessment Device, a self-report measure of family functioning. 相似文献75.
76.
77.
78.
79.
Introduction
Although ependymoma is the third most common pediatric brain tumor, we know little about the genetic/epigenetic basis of its initiation, maintenance, or progression. This is due in part to the heterogeneity of the disease, as well as the small sample size of the cohorts analyzed in most studies. 相似文献80.
Peter Angelos 《World journal of surgery》2009,33(4):609-611